A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Acute Pain
Interventions
DRUG

CR845

CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.

DRUG

Placebo

Matching placebo administered using same dosing algorithm as the active arm

Trial Locations (1)

84124

Jean Brown Research, Salt Lake City

Sponsors
All Listed Sponsors
lead

Cara Therapeutics, Inc.

INDUSTRY